US HIV research priorities shift from basic and clinical to implementation science

5 October 2026. Related: Early access, Treatment strategies, Guidelines, Activism & advocacy.

Simon Collins, HIV i-Base

On 5 October 2026, the US NIH Office of AIDS Research released a 35-page report outlining a roadmap for the NIH-funded research programme until 2030.

As the US research budget is still so much larger than any other country, this programme has international relevance, especially with US Government policy since 2025 reducing support for international and global research.

Most significantly, the plan prioritises implementation research, actively moving away from basic and clinical science.

This could be interpreted as no longer needing to continue to invest in pipeline compounds, vaccine research or clinical trials because the current drugs are good enough.

An info graphic at the start of the report shows that out of every 100 people living with HIV in the US, 13 don’t know their HIV status, 34 are not engaged in care (and therefore not on ART) and 43 are not virally suppressed.

This seems to deliberately avoid using UNAIDS 95:95:95 targets which would work out as 87:75:76, significantly lower than many African countries with much larger HIV epidemics.

The infographic is based on 2022 data, the latest available.

Reference

US NIH Office of AIDS Research. FY 2026–2030 NIH Strategic Plan for HIV and HIV-Related Research. (5 October 2026).
https://oar.nih.gov/hiv-policy-and-research/strategic-plan (web page)
https://oar.nih.gov/sites/g/files/mnhszr366/files/NIH-HIV-Strategic-Plan-508.pdf (PDF file)